July 25, 2014 8:06 PM ET

Pharmaceuticals

Company Overview of Biological E. Limited

Company Overview

Biological E. Limited develops, produces, markets, and supplies preventive medicines, vaccines, sera, and pharmaceutical products. It offers pediatric vaccines, including DPT, TT, and ATS; adult vaccines; natural biological extract molecules, such as DTP and tetanus toxoid; and anti snake venom, anti-tetanus serum, heparin, and the coscopin range. The company also provides pharmaceutical products in various segments, including asthma, cough management and digestive enzymes, nutraceuticals, anti-infectives, anticoagulants, and analgesics and antipyretic in solid dosage forms, liquid orals and syrups, parenterals, and active pharmaceutical ingredients. Biological E. Limited sells drugs to dire...

18/1&3, Azamabad

Hyderabad,  500 020

India

Founded in 1953

Phone:

91 40 3021 3999

Fax:

91 40 2761 5309

Key Executives for Biological E. Limited

Managing Director and Director
Chief Operating Officer
Age: 61
Senior Vice President of Quality
Senior Vice President of Technical Operations
Senior Vice President of Development
Compensation as of Fiscal Year 2014.

Biological E. Limited Key Developments

Biological E. Limited Presents at BioPharma India 2013, Nov-25-2013 through Nov-26-2013

Biological E. Limited Presents at BioPharma India 2013, Nov-25-2013 through Nov-26-2013. Venue: Hyatt Regency, Mumbai, Maharashtra, India. Presentation Date & Speakers: Nov-25-2013, Arani Chatterjee, Senior Vice President, Clinical Research. Nov-26-2013, Arani Chatterjee, Senior Vice President, Clinical Research.

Biological E Reportedly Plans 25% Stake Sale

Biological E. Limited intends to divest 25% stake to financial or strategic investors in order to raise about INR 6.20 billion ($ 100 million), three persons with knowledge of the development said. Last week, Biological E appointed E&Y as advisor for the stake sale, the persons said. The company plans to use the funds to launch new products, expand its research and development facilities and buy assets overseas. One of the persons the promoters could sell up to 25% and were looking at a valuation of between $400 million - $500 million.

Biological E Reportedly To Sell Minority Stake In Business

Biological E. Limited is seeking to raise funds by selling a minority stake in the company, two people close to the development, who did not wish to be identified said. At least half a dozen private equity funds are considering the investment opportunity, people added. "With WHO approval for its vaccine on its side, Biological (Biological E) has become a very interesting investment opportunity for investors," said an investment banker who did not wish to be identified. "The idea is to raise capital for minority stake, which could be either from PE funds or a strategic investor," said another investment banker, who spoke on condition of anonymity. Biological E's spokesperson declined to comment and Mahima Datla, Managing Director of Biological E did not respond to e-mails seeking comment to Mint.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Biological E. Limited, please visit www.biologicale.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.